Welcome to JGOG

Greetings from the President

Takayuki Enomoto, President, JGOG
(Niigata University Medical & Dental Hospital.)

The non-profit Japanese Gynecologic Oncology Group (JGOG) is a clinical research group that works with major Universities and Cancer Centers throughout the country in an effort to establish the optimal and latest diagnostic and therapeutic methods for patients with gynecologic malignancies.

JGOG has a long history, and it was developed as a gynecological chemotherapy research group in 1982, the year following the establishment of cervical cancer chemotherapy research group in 1981 by Professor Kiichiro Noda, and in 2002 We have obtained certification of NPO corporation as non-profit organization gynecology malignancy research organization and reached at present. Meanwhile, Kiichiro Noda will serve as chairman for 28 years until 2008, and Kazunori Ochiai will serve as chairman for six years from 2009 to 2014 and Toru Sugiyama for four years from 2015 to 2018. It is done. As of 2018, it has become a very large clinical research group with 181 participating institutions and 1023 regular memberships, while many high quality clinical research papers have been published in leading medical journals such as Lancet Oncology, Journal of Clinical Oncology. We have announced.

Now, JGOG is in a period of big change.
Also in gynecologic malignancies, elucidation of molecular mechanisms such as genomic / epigenomic abnormalities involved in canceration, tumor microenvironment, cross talk between cells, involvement of immune surveillance, etc. progressed, and development competition for molecularly targeted drugs flourished It has become. Furthermore, in Europe and the United States, many clinical trials have been conducted using a combination of molecularly targeted drugs that have different mechanisms of action, such as angiogenesis inhibitors, PARP inhibitors, and immune checkpoint inhibitors. In addition, as one of the immune checkpoint inhibitors has been expanded for indications for solid cancer of MSI-High, the basket test from the clinical trial performed by the previous organ (The target case is selected by the search for molecular marker The way in which clinical trials are conducted has significantly changed, and JGOG needs to be reorganized into a system that meets current needs. In addition, since company donations are decreasing year by year and the cost required for clinical research will further increase in the future, we will be making competitive funds such as commissioned clinical research, doctor-led trials, and Japan Medical Research and Development Organization (AMED). It is necessary to create a system that can be acquired For this purpose, the Translational Research (TR) Committee has been set up as an independent committee to propose and conduct clinical trials using molecularly targeted drugs, and to determine the rules for applying and acquiring external funds, and JGOG will continue to work on the world I would like to create a system that can perform clinical research at a high level.

Toru Sugiyama, the Former President of JGOG, has been working not only with Gynecologic Cancer Inter-Group (GCIG) and Korean Gynecologic Oncology Group (KGOG) but with other Asian countries, but in the future development of JGOG We believe that further strengthening of international exchange is an important issue. As well as creating a system that can actively participate in the clinical research of GCIG, it further deepens the collaboration with KGOG, Shanghai Gynecologic Oncology Group (SGOG) and Taiwanese Gynecologic Oncology Group (TGOG). I would like to establish the position of Asian leader.

Toru Sugiyama mentioned "clinical research," "education," and "sharing all perspectives" as the three arrows of JGOG. I would like to continue and develop these three pillars in the future. In clinical research, as mentioned above, we want to establish a system that enables translational research in collaboration with universities and research institutes, as well as drafting and carrying out research using molecular-targeted drugs that are increasingly developed from now on think. In education, I would like to add a course on TR to the educational seminar for young doctors held in summer, and to continue and develop it. JGOG has been conducting clinical research as a registered member of many hospitals as well as universities and cancer centers. Active support for JGOG by all medical professionals involved in gynecological malignancy treatment to establish optimum and latest diagnosis and treatment for gynecological malignancy For future development of JGOG I think it's important. We look forward to your continued guidance and encouragement.

January 2019

  • Organization Chart
  • Board of Directors
  • Crinical Trial
  • Achievement
  • JGOG COI Policy
  • Newsletter
  • Related Links

JGOG Administration Office
4F, Komatsu Building, 6-22, Kagurazaka, Shinjuku-ku,
Tokyo, 162-0825,